The presence of FLT3-ITD mutations in patients with acute myeloid leukemia (AML) is associated with poor clinical outcome. FLT3 tyrosine kinase inhibitors (TKIs), although effective in kinase ablation

NIAID Data Ecosystem20

Additional file 13 of Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells

白血病耐药性

核苷类似物治疗响应

Additional file 13: Supplementary Table 4. Characteristics of AML patients analysed in the data presented in Fig. 3.

Figshare2021-10-12 更新30

Mitoxantrone-liposome sensitizes Flt3-ITD acute myeloid leukemia to gilteritinib treatment

FLT3靶向治疗

癌症药物协同效应

FMS-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in acute myeloid leukemia (AML), and is associated with a poor prognosis and high relapse rate. Gilteritinib, as a second-generati

NIAID Data Ecosystem20